ClinicalTrials.gg
WithdrawnNCT06083675Updated Feb 26, 2024

Research Study to Compare Semaglutide Tablets With Empagliflozin or Metformin Tablets in People With Type 2 Diabetes

A Phase 3 interventional study of Semaglutide and Empagliflozin in Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Withdrawn at 101 sites in 13 countries. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2024-02-26.

Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Due to internal reprioritization, trial was cancelled.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 163 studies testing semaglutide in Diabetes Mellitus, Type 2 — 35 open to participants now, 45 under way, 9 of them phase 3. Semaglutide · Diabetes Mellitus, Type 2.

Enrollment
161st of 163
0 · median 104
Started
2024
with 17 others
Phase 3
57 of 163
7 open now
Registered
124th of 163
by date
Lead sponsor
89 of 163
Novo Nordisk A/S

Among the 163 studies testing semaglutide in Diabetes Mellitus, Type 2, this one is the 161st largest by enrollment, is one of 18 that started in 2024, is one of 57 in phase 3, and was the 124th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

35 of the 163 studies testing semaglutide in Diabetes Mellitus, Type 2 are open now, in 12 countries. Recruiting first, the newest first:

30 more — sign in →

By country, each count listing its studies:

All 35 open studies →

About semaglutide

Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 163 studies testing semaglutide in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

This study compares the medicines semaglutide with empagliflozin or metformin in people with newly diagnosed type 2 diabetes. This study will look mainly at how well participant's blood sugar and body weight are controlled when they are taking the study medicines. Participants will either get semaglutide tablets, empagliflozin tablets or metformin tablets. Which treatment participants will get is decided by chance. Currently, doses of 3 milligram (mg), 7 mg and 14 mg semaglutide tablets (Rybelsus) can be prescribed in some countries. 25 mg and 50 mg semaglutide tablets are new doses. 10 mg and 25 mg empagliflozin tablets (Jardiance) can be prescribed in some countries. 500 mg metformin tablets (STADA) can be prescribed in some countries. Participants will get 1 to 4 tablets per day for 104 weeks. The study will last for about 2 years and 7 weeks (111 weeks). Participants should not have been treated for weight management 90 days before screening or never been treated with any medicine for type 2 diabetes (except diabetes during pregnancy) before screening. Women cannot take part if pregnant, breast-feeding or plan to get pregnant during the study period.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female.
  • Age ≥18 and \<60 years at the time of signing the .
  • Diagnosed with type 2 diabetes mellitus within 24 months from the day of screening.
  • of 7.0-10.0% (53-86 millimoles per mole [mmol/mol])
  • ≥25.0 kilogram per square meter (kg/m\^2)

Exclusion criteria

Exclusion Criteria:

  • Treatment with any medication for the indication of diabetes. Prior insulin treatment for gestational diabetes is allowed.
  • Treatment with any medication for the indication of weight management 90 days prior to screening.
  • Renal impairment measured as estimated (eGFR) \<60 milliliters per minute per 1.73 meter sqaure (mL/min/1.73 m\^2) at screening.
  • Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
  • C-peptide \<1.5 nanograms per milliliter (ng/mL) at screening.
  • Positive insulinoma associated-protein 2 (IA-2) antibodies ≥7.5 Units/mL or anti-glutamic acid decarboxylase (anti-GAD) antibodies greater than (>) 5.0 international units per milliliter (IU/mL).
  • Impaired liver function, defined as (ALT) ≥2.5 times or >1.5 times upper normal limit at screening.
  • History of major surgical procedures involving the stomach potentially affecting absorption of trial products (example subtotal or total gastrectomy, sleeve gastrectomy, gastric bypass surgery) or current presence of gastrointestinal implant.
  • Presence of gastrointestinal disorders affecting absorption of drugs and/or nutrients, as judged by the investigator.
  • Any for empagliflozin or metformin according to local labelling at the investigator's discretion
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Semaglutide 25 mg

    Participants will receive 25 mg oral semaglutide once daily in maintenance period after dose escalation period.

    Drug: Semaglutide

  • Experimental
    Semaglutide 50 mg

    Participants will receive 50 mg oral semaglutide once daily in maintenance period after dose escalation period.

    Drug: Semaglutide

  • Experimental
    Empagliflozin 25 mg

    Participants will 25 mg empagliflozin oral once daily in maintenance period after dose escalation period.

    Drug: Empagliflozin

  • Experimental
    Metformin 2000 mg

    Participants will receive metformin 1000 mg orally twice daily (total 2000 mg) in maintenance period after dose escalation period.

    Drug: Metformin

Interventions

06

What researchers measure

Primary outcomes

  1. Change in glycated haemoglobin (HbA1c)

    Measured in Percentage (%)-points.

    Time frame: From randomisation (week 0) to week 52

Secondary outcomes

  1. Change in body weight

    Measured in kilograms (kg).

    Time frame: From randomisation (week 0) to week 52

  2. Change in fasting plasma glucose (FPG)

    Measured in millimoles per liter (mmol/L).

    Time frame: From randomisation (week 0) to week 52

  3. Change in 7 point self measured plasma glucose (SMPG) mean profile

    Measured in mmol/L.

    Time frame: From randomisation (week 0) to week 52

  4. Change in 7-point self-measured plasma glucose (SMPG) mean post prandial increments

    Measured in mmol/L.

    Time frame: From randomisation (week 0) to week 52

  5. Relative change in body weight

    Measured in Percentage (%).

    Time frame: From randomisation (week 0) to week 52

  6. Change in waist circumference

    Measured in centimeters (cm).

    Time frame: From randomisation (week 0) to week 52

  7. HbA1c less than or equal to (≤) 6.5% (Yes/No)

    Measured as count of participants.

    Time frame: At week 52

  8. HbA1c less than (<) 7% (Yes/No)

    Measured as count of participants.

    Time frame: At week 52

  9. Body weight reduction greater than equal to ( ≥) 5% (Yes/No)

    Measured as count of participants.

    Time frame: At week 52

  10. Body weight reduction ≥10% (Yes/No)

    Measured as count of participants.

    Time frame: At week 52

  11. Body weight reduction ≥15% (Yes/No)

    Measured as count of participants.

    Time frame: At week 52

  12. HbA1c <7.0% and body weight reduction ≥5% (Yes/No)

    Measured as count of participants.

    Time frame: At week 52

  13. Change in systolic blood pressure

    Measured in millimeters of mercury (mmHg).

    Time frame: From randomisation (week 0) to week 52

  14. Change in diastolic blood pressure

    Measured in mmHg.

    Time frame: From randomisation (week 0) to week 52

  15. Change in High-sensitivity C-reactive protein (hsCRP)

    Measured in milligrams per liter (mg/L).

    Time frame: From randomisation (week 0) to week 52

  16. Time to rescue medication

    Measured in days.

    Time frame: From randomisation (week 0) to week 104

  17. Change in HbA1c

    Measured in %-points.

    Time frame: From randomisation (week 0) to week 104

  18. Change in body weight

    Measured in kg.

    Time frame: From randomisation (week 0) to week 104

  19. Change in FPG

    Measured in mmol/L.

    Time frame: From randomisation (week 0) to week 104

  20. Change in 7 point SMPG mean profile

    Measured in mmol/L.

    Time frame: From randomisation (week 0) to week 104

  21. Change in 7-point SMPG mean post prandial increments

    Measured in mmol/L

    Time frame: From randomisation (week 0) to week 104

  22. Relative change in body weight

    Measured in Percentage.

    Time frame: From randomisation (week 0) to week 104

  23. Change in waist circumference

    Measured in cm.

    Time frame: From randomisation (week 0) to week 104

  24. HbA1c ≤6.5% (Yes/No)

    Measured as count of participants.

    Time frame: At week 104

  25. HbA1c <7.0% (Yes/No)

    Measured as count of participants.

    Time frame: At week 104

  26. Body weight reduction ≥5% (Yes/No)

    Measured as count of participants.

    Time frame: At week 104

  27. Body weight reduction ≥10% (Yes/No)

    Measured as count of participants.

    Time frame: At week 104

  28. Body weight reduction ≥15% (Yes/No)

    Measured as count of participants.

    Time frame: At week 104

  29. HbA1c <7.0% and body weight reduction ≥5% (Yes/No)

    Measured as count of participants.

    Time frame: At week 104

  30. Change in systolic blood pressure

    Measured in mmHg.

    Time frame: From randomisation (week 0) to week 104

  31. Change in diastolic blood pressure

    Measured in mmHg.

    Time frame: From randomisation (week 0) to week 104

  32. Change in hsCRP

    Measured in mg/L.

    Time frame: From randomisation (week 0) to week 104

  33. Treatment emergent adverse events

    Measured as count of events.

    Time frame: From randomisation (week 0) to week 52

  34. Number of severe (level 3) or clinically significant (level 2) hypoglycaemic episodes

    Measured as count of episodes.

    Time frame: From randomisation (week 0) to week 52

  35. Treatment emergent adverse events

    Measured as count of events.

    Time frame: From randomisation (week 0) to follow-up visit (week 109)

  36. Number of severe (level 3) or clinically significant (level 2) hypoglycaemic episodes

    Measured as count of episodes.

    Time frame: From randomisation (week 0) to follow-up visit (week 109)

  37. Change in Control of Eating Questionnaire (CoEQ) score - Craving Control domain

    CoEQ is a 19-item multidimensional patient reported outcome (PRO) that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). For the craving control subscale, the subscale score is reversed so that a higher score represents a greater level of craving control.

    Time frame: From randomisation (week 0) to week 52

  38. Change in CoEQ score - Craving for Savory domain

    CoEQ is a 19-item multidimensional PRO that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). For the craving savoury food subscale, higher score represents a greater level of craving.

    Time frame: From randomisation (week 0) to week 52

  39. Change in Impact of Weight on Quality of Life-Lite Clinical Trials (IWQOL-Lite-CT) score - Physical function domain

    IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. Composite scores (score range): Physical composite (0-100), Psychosocial composite (0 100), Physical Function composite (0-100). Total score range (0-100).

    Time frame: From randomisation (week 0) to week 52

  40. Change in American Heart Association (AHA) Life's Simple 7 summary score

    The AHA recommends focusing on 7 cardiovascular health factors (smoking, BMI, physical activity, diet, total cholesterol, blood pressure, and fasting blood glucose) for early or primary prevention of cardiovascular disease. The 7 health factors are each categorized as ideal, intermediate, or poor. Scales range from 0 (minimum) to 14 (maximum). Higher score represents a greater level of health.

    Time frame: From randomisation (week 0) to week 52

  41. Change in CoEQ score - Craving Control domain

    CoEQ is a 19-item multidimensional PRO that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). For the craving control subscale, the subscale score is reversed so that a higher score represents a greater level of craving control.

    Time frame: From randomisation (week 0) to week 104

  42. Change in CoEQ score - Craving for Savory domain

    CoEQ is a 19-item multidimensional PRO that assesses the experience of hunger, satiety, and severity and type of food cravings. CoEQ consists of 4 subscales that measure craving control (5 items), positive mood (4 items), craving for sweet (4 items), craving for savoury food (4 items), and 2 single items that address hunger and satiety. Each item is evaluated on a 0-10 (i.e., 11-point) numeric rating scale. The total score for each subscale is calculated as the sum of the item scores divided by the number of items in the subscale. Scores ranges are thus: Craving Control 0-50/5 = 0-10); Positive Mood (0-40/4 = 0-10); Craving Sweet (0-40/4 = 0-10); Craving Savoury food (0-40/4 = 0-10); single items that address hunger and satiety (0-10). For the craving savoury food subscale, higher score represents a greater level of craving.

    Time frame: From randomisation (week 0) to week 104

  43. Change in IWQOL-Lite-CT score - Physical function domain

    IWQOL-Lite-CT measures weight-related physical and psychosocial functioning. The measure consists of 20 items yielding 3 composite scores, and 1 total score. Higher scores indicate better levels of functioning. Composite scores (score range): Physical composite (0-100), Psychosocial composite (0 100), Physical Function composite (0-100). Total score range (0-100).

    Time frame: From randomisation (week 0) to week 104

  44. Change in AHA Life's Simple 7 summary score

    The AHA recommends focusing on 7 cardiovascular health factors (smoking, BMI, physical activity, diet, total cholesterol, blood pressure, and fasting blood glucose) for early or primary prevention of cardiovascular disease. The 7 health factors are each categorized as ideal, intermediate, or poor. Scales range from 0 (minimum) to 14 (maximum). Higher score represents a greater level of health.

    Time frame: From randomisation (week 0) to week 104

07

Study locations

101 sites
  • Hillcrest Family Health Center
    Waco, Texas 76708, United States
  • Instituto de Ciências Farmacêuticas
    Goiânia, Goias 74935-330, Brazil
  • Núcleo de Pesquisa Clínica do Rio Grande do Sul Ltda.
    Porto Alegre, Rio Grande Do Sul 90430-001, Brazil
  • CPQuali Pesquisa Clínica Ltda
    São Paulo, Sao Paulo 01228-000, Brazil
  • CPCLIN - Centro de Pesquisas Clínicas
    São Paulo, Sao Paulo 01228-200, Brazil
  • Individual Practice For Specialized Outpatient Medical Care Doctor Miglena Rizova Ltd.
    Kyustendil, 2500, Bulgaria
  • Diagnostic-Consultative Centre "Sveti Georgi" Eood
    Plovdiv, 4002, Bulgaria
  • "Aipsomcemd - Dr. Petya Georgieva" Eood
    Plovdiv, 4018, Bulgaria
  • ''Aipsomcidemd - Dr. Lilyana Bodurova-Troharova" Eood
    Samokov, 1000, Bulgaria
  • "Medical center Medishtit Velisia" OOD
    Stara Zagora, 6000, Bulgaria
  • Diagnostic Consulting Center 1 Velingrad EOOD
    Velingrad, 4600, Bulgaria
  • MHAT- Hristo Botev AD
    Vratsa, 3000, Bulgaria
  • Poliklinika SLAVONIJA OSIJEK
    Osijek, Osječko - Baranjska Županija 31000, Croatia
  • Opca bolnica Karlovac
    Karlovac, 47000, Croatia
  • Specijalna bolnica Krapinske Toplice - Endokrinologija
    Krapinske Toplice, 49217, Croatia
  • Opca bolnica Pula
    Pula, 52100, Croatia
  • Specijalna bolnica Medico
    Rijeka, 51000, Croatia
  • Iatriko Psychicou Private Clinic
    Athens, 115 25, Greece
  • "Laiko" General Hospital of Athens
    Athens, GR-11527, Greece
  • Iatriko Athinon (Athens Medical Canter)
    Athens, GR-15125, Greece
  • Iatriko Athinon 'Palaiou Falirou'
    Athens, GR-17562, Greece
  • University Hospital of Athens ATTIKON
    Haidari-Athens, GR-12462, Greece
  • University General Hospital of Ioannina,Internal Medicine
    Ioannina, 45500, Greece
  • General Hospital of Thessaloniki 'G. Gennimatas
    Thessaloniki, GR-54635, Greece
  • EUROMEDICA Gen Clinic The/ki, Endocrin,Metabolism,Diabetes
    Thessaloniki, GR-54643, Greece
  • "Thermi" Private Hosital
    Thessaloniki, GR-57001, Greece
  • General Hospital of Thessaloniki "G.Papanikolaou"
    Thessaloniki, GR-57010, Greece
  • ClinDiab Egészségügyi Szolgáltató és Kereskedelmi Kft.
    Budapest, 1089, Hungary
  • Belinus Bt.
    Debrecen, 4025, Hungary
  • Osmania General Hospital
    Hyderabad, A.p. 500 063, India
  • Endolife Specialty Hospitals
    Guntur, Andhra Pradesh 522001, India
  • Yalamanchi Hospitals and Research centres pvt ltd
    Vijaywada, Andhra Pradesh 520002, India
  • Navneeth Memorial Hospital
    Ahmedabad, Gujrat 380009, India
  • Govt Medical College
    Vadodara, Gujrat 390001, India
  • Ramaiah Memorial Hospital
    Bangalore, Karnataka 560054, India
  • Lifecare Hospital and Research Centre
    Bangalore, Karnataka 560092, India
  • K R Hospital
    Mysuru, Karnataka 570001, India
  • TOTALL Diabetes Hormone Institute
    Indore, Madhya Pradesh 452010, India
  • Goa Medical College
    Goa, Maharashtra 403 202, India
  • Excel Endocrine Centre
    Kolhapur, Maharashtra 416008, India
  • Seth GS Medical College & KEM Hospital
    Mumbai, Maharashtra 400012, India
  • BSES MG hospital
    Mumbai, Maharashtra 400058, India
  • Ashirwad Hospital and Research Centre
    Thane, Maharashtra 421004, India
  • Acharya Vinoba Bhave Rural Hospital, Sawangi Meghe, Wardha
    Wardha, Maharashtra 442001, India
  • Maulana Azad Medical College
    Delhi, New Delhi 110002, India
  • Dayanand Medical College & Hospital_Ludhiana
    Ludhiana, Punjab 141001, India
  • Jawahar Lal Nehru Govt. Medical College
    Ajmer, Rajasthan 305001, India
  • Diabetes, Thyroid and Endocrine Centre
    Jaipur, Rajasthan 302006, India
  • M.V.Hospital for Diabetes Pvt. Ltd.
    Chennai, Tamil Nadu 600 013, India
  • Gandhi Hospital & Medical college
    Hyderabad, Telengana 500003, India
  • Yashoda hospital
    Hyderabad, Telengana 500082, India
  • Medanta Lucknow Hospital
    Lucknow, Uttar Pradesh 226030, India
  • BP Poddar Hospital
    Kolkata,, West Bengal 700053, India
  • Swasthya Diabetes Care
    Ahmedabad, 390013, India
  • Aligarh Muslim University
    Aligarh, 202002, India
  • Sparsh Hospital, Bhubaneshwar
    Bhubaneshwar, 751007, India
  • All India Institute of Medical Sciences (AIIMS), Nagpur
    Maharashtra, 441108, India
  • JIPMER
    Puducherry, 605006, India
  • Lifepoint Multispecialty Hospital
    Pune, 411057, India
  • Mahatma Gandhi Memorial Hospital, Sherpura
    Warangal, 506002, India
  • Hospital Miri
    Sarawak, Miri 98000, Malaysia
  • Klinik Kesihatan Kuang
    Rawang, Selangor 48050, Malaysia
  • Klinik Kesihatan Bintulu
    Bintulu, 97000, Malaysia
  • Klinik Kesihatan Greentown Ipoh
    Ipoh, 30450, Malaysia
  • Klinik Kesihatan Cheras Baru
    Kuala Lumpur, 56100, Malaysia
  • Hospital Melaka
    Melaka, 75400, Malaysia
  • Hospital Seri Manjung
    Seri Manjung, 32040, Malaysia
  • Hospital Sultan Haji Ahmad Shah
    Temerloh,Pahang, 28000, Malaysia
  • Medical Care and Research S. A de C.V
    Merida, Yucatan 97070, Mexico
  • Eme Red Hospitalaria
    Mérida, Yucatán 97070, Mexico
  • FAICIC S. de R.L. de C.V.
    Veracruz, 91900, Mexico
  • Clinmedica Research sp. z o.o.
    Skierniewice, Lodzkie 96-100, Poland
  • ETG Siedlce
    Siedlce, Masovian 08-110, Poland
  • NZOZ Vita-Diabetica Malgorzata Buraczyk
    Bialystok, Podlaskie Voivodeship 15-879, Poland
  • Centrum Medyczne Intercor Sp. z o.o.
    Bydgoszcz, 85-605, Poland
  • Diab Serwis Popenda Spółka Jawna
    Chorzów, 41-500, Poland
  • NZOZ Euromedica
    Grudziadz, 86-300, Poland
  • Etyka Ośrodek Badań Klinicznych Tomasz Pesta S.K.A.
    Olsztyn, 10-117, Poland
  • ENDOPRACTICA W.Beker, D.Mielczarek, P.Mielczarek, J.Struzik spółka cywilna
    Opole, 45-301, Poland
  • NZOZ NEURO-KARD Ilkowski i Partnerzy Spółka Partnerska Lekarzy
    Poznań, 61-853, Poland
  • Centrum Medyczne Oporow
    Wroclaw, 52-416, Poland
  • Centra Medyczne Medyceusz Sp. z o.o.
    Łódź, 91-053, Poland
  • Trialmed CRS
    Piotrków Trybunalski, Łódzkie 97-300, Poland
  • Institutul National De Diabet Nutritie Si Boli Metabolice Prof.Dr.N.Paulescu Bucuresti- Ion Movila
    Bucharest, Bucurestii 020475, Romania
  • Sc Mediab Srl
    Targu Mures, Mures 540142, Romania
  • Sc Mediab Srl
    Tirgu Mures, Mures 540142, Romania
  • Clinica Grivitei 224 S.R.L.
    Braila, 810197, Romania
  • SC Nutrilife SRL
    Bucharest, 013764, Romania
  • Diabet Med SRL
    Bucuresti, 050913, Romania
  • S.C. Dianutrilife Medica S.R.L.
    Ploiesti, 100561, Romania
  • Clinica Korall S.R.L. Satu Mare
    Satu-Mare, 440055, Romania
  • Healthcare centre Zvezdara
    Belgrade, RS 11050, Serbia
  • Healthcare centre Kragujevac
    Kragujevac, RS 34000, Serbia
  • Healthcare centre Nis
    Nis, RS 18000, Serbia
  • Siriraj Hospital
    Bangkok Noi, Bangkok 10700, Thailand
  • Thammasat University Hospital
    Klong Luang, Pathum Thani 12120, Thailand
  • Rajavithi Hospital
    Bangkok, 10400, Thailand
  • Ramathibodi Hospital
    Bangkok, 10400, Thailand
  • Maharaj Nakorn Chiang Mai Hospital
    Chiang Mai, 50200, Thailand
  • Srinagarind Hospital
    Khon Kaen, 40002, Thailand

Showing the first 100 of 101 sites across 13 countries. Choose a country and city above to see the rest.

08

References and documents

Individual participant data

Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com

Data sharing details ↗ · novonordisk-trials.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Jan 2024; primary completion for Jan 2025, 11 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2023
First posted
Oct 16, 2023
StartEst.
Jan 26, 2024
Primary completionEst.
Jan 24, 2025
CompletionEst.
May 28, 2027
Last update
Feb 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06083675
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Oct 16, 2023
Start date
Jan 26, 2024 (estimated)
Primary completion
Jan 24, 2025 (estimated)
Completion
May 28, 2027 (estimated)
Last update
Feb 26, 2024

Study contacts

Clinical Transparency (dept. 2834)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion